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The human regulatory complement component C4b-binding protein (C4BP) circulates in plasma either as a free protein or in a bimolecular complex 
with the vitamin K-dependent protein S. The major form of C4BP is composed of 7 identical, disulfide-linked 70 kDa subunits (a-chains), the 
arrangement of which gives the C4BP molecule a spider-like appearance. Recently, we identified a unique 45 kDa subunit (B-chain) in C4BP. We 
have now isolated a subpopulation of C4BP, which does not bind protein S. This C4BP species, which had a molecular weight slightly lower than 
that of the predominant form, was found to lack the p-chain. Another lower molecular weight form of C4BP was also purified. It contained the 
/?-chain and was efficient in binding protein S. Its subunit composition was judged to comprise six a-chains and one p-chain. These results indicate 
C4BP in plasma to be heterogeneous at a molecular level vis-a-vis subunit composition and/or protein S binding ability and provide support for 
the concept hat the p-chain of C4BP contains the single protein S binding site. 
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1. INTRODUCTION 
Control of complement activation is mediated by a 
number of proteins, either circulating in plasma or 
associated with the cell membranes; see review by Law 
and Reid [l]. C4b-binding protein (C4BP), a plasma 
glycoprotein, accelerates the decay of the classical 
pathway C3-convertase and acts as cofactor to factor I, 
a serine protease, in the cleavage of C4b [2-61. 
Approximately 50% of C4BP circulates in plasma in 
complex with the anticoagulant vitamin K-dependent 
protein S [7-91. Protein S has a high affinity for 
negatively charged phospholipid membranes, and has 
been proposed to act as a mobile receptor for C4BP, at- 
taching it to the surface of activated or injured cells 
[8-l 11. In the regulation of the coagulation system, 
protein S is a cofactor to activated protein C in the 
degradation of the thrombin-activated factors V and 
VIII [12,13]. As only free protein S has cofactor activi- 
ty, C4BP would seem to have a regulatory function in 
the coagulation system [14,15]. 
composed of 7 identical 70 kDa subunits (referred to 
here as a-chains), each of which contains one C4b- 
binding site [8,16- 191. Electron microscopy studies 
showed the subunit arrangement o give the C4BP 
molecule a spider-like structure [l&19]. The o-chain 
contains 8 homologous repeats, each approximately 60 
amino acid residues long [17,20]. Similar, so-called 
short consensus repeats (SCR), have been found in 
other proteins, several of which have C3b or C4b 
binding properties [21,22]. Recently, we reported the 
presence of a novel disulfide-linked 45 kDa subunit 
(referred to here as the P-chain) in C4BP, and ex- 
perimental data suggested it to contain the protein S 
binding site [23]. Amino acid and nucleotide sequenc- 
ing of the P-chain show it to be homologous to the (Y- 
chain, containing three SCRs and a 60 amino acid 
residues long non-homologous carboxy-terminal region 
(Hillarp and Dahlback, submitted). 
The major form of C4BP (M 570 000) in plasma is 
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Two forms of C4BP differing slightly from each 
other in molecular weight, have been identified 
[2,4,7,8,16,17,23-251. They have been designated 
C4BP-high and C4BP-low, and the difference at the 
molecular level between the two forms has not been 
elucidated. We have observed that approximately 80% 
of C4BP in plasma binds to barium citrate, probably 
due to interaction with protein S [8]. C4BP-low which 
was purified from the barium citrate supernatant was 
unable to bind protein S [8], but is was not investigated 
whether it contained the P-chain. Recently, we iden- 
tified another low molecular weight form of C4BP 
which binds to barium citrate [23]. This form binds 
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protein S and contains the P-subunit. Suzuki and 
Nishioka [26] have confirmed that C4BP-low, which 
can be purified from the supernatant after barium 
citrate adsorption, is unable to bind protein S. They 
suggested this C4BP form to be composed of truncated 
a-chains, and proposed the protein S binding site of 
C4BP to be located in the eighth SCR of the a-chain. 
To correlate the protein S binding of C4BP to its 
subunit composition, we have now examined the 
C4BP-low form which does not bind protein S, for its 
P-chain content. We find this form of C4BP to lack the 
P-chain. This supports the concept that the single pro- 
tein S binding site on the C4BP molecule is located on 
the P-chain. 
2. EXPERIMENTAL 
2.1. Proteins 
C4BP was purified from fresh &rated human plasma in a 3-step 
procedure including barium citrate adsorption, polyethylene glycol 
precipitation and monoclonal antibody affinity chromatography. 
C4BP obtained from the barium citrate precipitate will be referred to 
here as C4BP-Ba, and that recovered from the barium citrate adsorb- 
ed plasma as C4BP-sup. To fresh titrated human plasma (obtained 
from the local blood bank) the following proteinase inhibitors were 
added: phenylmethanesulfonyl fluoride (1 mM), soybean trypsin in- 
hibitor (50 mg/l), benzamidine (10 mM) and 6-amino-n-hexanoic 
acid (10 mM). The purification was performed either on an ice-bath 
or at + 4°C. Barium chloride (1 M, 80 ml/l plasma) was added slowly 
to the plasma, which was then gently stirred for one hour. The 
barium citrate precipitate was collected by centrifugation at 
10 000x g for 30 min. The pellet was dissolved in 0.2 M EDTA, 
pH 7.4, and insoluble material removed by centrifugation. C4BP, 
both that recovered in the barium citrate eluate and that remaining 
in the barium adsorbed plasma, was precipitated by the addition of 
solid polyethylene glycol6 000 (5%, w/v). The precipitates were col- 
lected by centrifugation at 10 000 x g for 30 min, dissolved in 50 mM 
Tris-HCl, 0.15 M NaCl, pH 8.0, containing 0.1% Tween 20, and 
dialyzed against the same buffer. Finally, C4BP was purified using 
a monoclonal antibody against C4BP (M104) coupled to Affi-gel 10 
(BioRad). After washing of the column, first with dialysis buffer and 
then with 1 M NaCl containing 0.1% Tween 20, the bound C4BP was 
eluted with 0.1 M glycine, 0.5 M NaCl, pH 2.2. The eluate was im- 
mediately neutralized with Tris-base and dialyzed against 50 mM 
Tris-HCl, 0.15 M NaCl, pH 8.0. The solution was concentrated by 
ultrafiltration using a XM-50 membrane (Amicon) and stored at 
-70°C until used. The C4BP concentration was estimated from the 
absorbance at 280 nm using an extinction coefficient (1010, 1cm) of 
14.1 [27]. Human protein S was purified as previously described [28] 
and ‘251-labelled using Iodobeads (Pierce Chemical Co.) according to 
the manufacturer’s instructions. 
2.2. Antisera 
Polyclonal antisera against he individual C4BP subunits were rais- 
ed in rabbits. C4BP was reduced and alkylated and the o- and /3- 
chains separated on a large 5-15Vo SDS-PAGE (100 fig protein per 
well). After electrophoresis and staining of the gel (1% Coomassie in 
H20 for 30 min followed by destaining in HzO), the two subunits 
were cut out, and the gel sections homogenized with a glass hand- 
homogenizer in 1 ml 0.15 M NaCl. The homogenates were mixed 
with 1 ml complete Freunds adjuvant and used to immunize rabbits. 
The antiserum against the o-chain only recognized the reduced and 
alkylated a-chain. Presumably due to a small amount of fragmented 
o-chains in the p-chain preparation, the antiserum against he P-chain 
reacted weakly with reduced and alkylated o-chain, though this did 
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not adversely affect the interpretation of results. Both antisera 
reacted poorly with native C4BP. 
The monoclonal antibody (M 104), used for affinity 
chromatography purification of C4BP and immunoblotting, 
recognized an epitope in the N-terminal part of the or-chain (Hillarp 
and Dahlbiick, to be published elsewhere). 
2.3.Electrophoretic and blotting techniques 
SDS-PAGE was performed as described previously [29], using 
Maizel’s buffer system [30]. Two different linear gradient gels were 
used, 3-5% for intact C4BP and 5-15% for separation of the two 
subunits under reducing conditions. In the ‘sequential’ (unreduc- 
cd/reduced) SDS-PAGE analysis, unreduced C4BP was applied to 
the first gel (3-5%), and the stained bands were cut out and applied 
to the second gel (5-15%) after reduction. The technique has been 
described in more detail elsewhere [23]. The gels were stained with 
Coomassie brilliant blue R-250, and the relative amounts of the 
observed isotypes of C4BP were estimated by laser densitometry 
using an Ultroscan 2202 apparatus (LKB). Immune- and ligand blot- 
ting was performed with Immobilon (Millipore) as the membrane, us- 
ing procedures previously described [3 11. 
3. RESULTS AND DISCUSSION 
The C4BP that was purified from the supernatant 
plasma after barium adsorption, C4BP-sup, and that 
recovered from the barium citrate precipitate, C4BP- 
Ba, were both analyzed by means of low-percentage 
SDS-PAGE (fig.1). The proteins were either stained 
with Coomassie or transferred to Immobilon mem- 
branes for immunoblotting or ‘251-protein S ligand 
blotting. Both preparations, C4BP-Ba (lane A) and 
C4BP-sup (lane B), appeared as doublets and their high 
I ” .,: 
Coomassie 
A B A B 
Immunoblot Ligand blot 
Fig.1. Different C4BP forms demonstrated with SDS-PAGE, im- 
munoblotting and r2’I-protein S ligand blotting. The two different 
C4BP preparations C4BP-Ba (A) and C4BP-sup (B) were run on a 
3-5% gradient SDS-PAGE. The gels were either stained with 
Coomassie brilliant blue, or the protein was transferred to Im- 
mobilon membranes and analyzed with a monoclonal antibody 
(M104) directed against the o-chain of C4BP (immunoblot). The 
ability of C4BP to bind protein S was tested using radiolabelled pro- 
tein S (ligand blot). Approximately 1Opg of protein was applied to 
each lane. 
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molecular weight forms migrated to identical positions, 
and both were able to bind protein S. The two low 
molecular weight forms appeared to differ slightly 
from each other in molecular weight. The ‘low’ form in 
the C4BP-sup preparation had a slightly higher 
molecular weight than the corresponding form in 
C4BP-Ba. ‘251-labelled protein S ligand blotting clearly 
showed the ‘low’ form in the C4BP-Ba preparation to 
be able to bind protein S (lane A), whereas no protein 
S binding was observed to the predominant ‘low’ form 
in the C4BP-sup preparation (lane B). The weak signal 
obtained on ligand blotting, in the lower molecular 
weight region in lane B represents a molecular weight 
corresponding to the ‘low’ form seen in lane A. This 
suggests the presence of trace amounts of C4BP-low 
with intact protein S binding remaining in the superna- 
tant after barium adsorption. This trace component 
was not visible on Coomassie stained gels or on the im- 
munoblotting. The proportions of the Coomassie stain- 
ed bands in the two preparations were estimated by 
densitometric scanning of the stained gels. The ‘high’ 
and ‘low’ forms constituted 85% and 15%, respective- 
ly, in the C4BP-Ba preparation, whereas in the C4BP- 
sup preparation corresponding values were 20% and 
80%. Approximately 80% of C4BP in plasma binds to 
the barium citrate precipitate, leaving the remaining 
20% in the supernatant [8]. From these data it can be 
estimated that 70-75% of plasma C4BP is of the ‘high’ 
form, and that the two ‘low’ forms each comprise 
lo-15%. 
To ascertain whether protein S binding was cor- 
related with subunit composition, sequential SDS- 
Al A2 I31 82 
-45 kDa 
Fig.2. Presence of &chain in different C4BP forms demonstrated by 
immunoblotting after ‘sequential’ SDS-PAGE. C4BP-Ba (A) and 
C4BP-sup (B) were applied to a 3-5’70 gradient SDS-PAGE. The 
‘high’ (1) and ‘low’ (2) bands were cut out, reduced and applied to 
a 5-15% gradient SDS-PAGE. After electrophoresis, the separate 
C4BP chains were transferred to Immobilon and analyzed with an 
antiserum that recognized both chains. Approximately 50 pg of pro- 
tein was applied to the first gel. 
PAGE was performed (fig.2). In this analysis, the pro- 
tein bands seen in the low percentage gel were cut out, 
reduced, and applied to high percentage SDS-PAGE, 
and subsequently immunoblotted using a polyclonal 
antiserum that reacted both with CY- and P-chains. The 
P-chain was clearly demonstrated to be present in the 
three protein S-binding C4BP forms. However, the 
‘low’ form in the C4BP-sup preparation, which did not 
bind protein S, contained no detectable P-chain. Also 
of note is the finding that the a-chains in the 4 lanes 
migrated to identical positions, indicating that they 
were identical in molecular weight. Another polyclonal 
antiserum, specifically recognizing the reduced and 
alkylated a-chain, did not react with the 45 kDa band 
in any of the lanes, showing that this band indeed 
represented a distinct molecular species, and not a 
degradation product of the a-chains (results not 
shown). These results indicate the presence in plasma of 
a subpopulation of C4BP lacking &chain and protein 
S binding ability, and constitute support for the con- 
cept that the single protein S binding site on C4BP is 
located on the P-chain. 
Suzuki and Nishioka [26] described a monoclonal an- 
tibody (MFbp 16) that failed to recognize C4BP-low 
purified from the barium citrate supernatant. How- 
ever, it reacted with C4BP-low purified from the 
barium citrate precipitate. This suggests the C4BP-low 
remaining in the barium citrate supernatant o lack an 
antigenic structure which is present in the other C4BP 
forms. Suzuki and Nishioka concluded that the protein 
S binding site as well as the epitope for the monoclonal 
antibody was located in the carboxy-terminal of the (Y- 
chain, and that the difference between the ‘high’ and 
‘low’ molecular weight forms of C4BP resides in the CY- 
chain. However, our present results suggest an alter- 
native explanation, i.e. that the MFbp 16 binds to the 
P-chain of C4BP. Suzuki and Nishioka suggested the CY- 
chain of C4BP-low, purified from the barium superna- 
tant, to be truncated. However, using a high resolution 
SDS-PAGE system, we found no difference in mo- 
lecular weight between the a-chains of the different 
C4BP forms. 
We propose that the molecular weight differences 
between the various C4BP forms may be explained by 
differences in subunit composition. The results of 
several approaches indicate the major C4BP form in 
plasma to contain 7 a-chains. High resolution electron 
microscopy findings suggest C4BP to contain 7 extend- 
ed C4b-binding tentacles (each corresponding to one (Y- 
chain) and one smaller subunit, which bind protein S 
(corresponding to the P-chain) [ 191. When chymotryp- 
sin digestion of C4BP was monitored on SDS-PAGE, 
seven 48 kDa a-chain fragments were found to be 
released [181. Perkins et al. [27], using X-ray scattering, 
reported the number of subunits to be 7.4 + 1. These 
results are compatible with our conclusion that the ma- 
jor species of C4BP contains 7 a-chains and one p- 
55 
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Fig.3. Schematic model of subunit composition of different C4BP 
forms. The SDS-PAGE pattern of C4BP-Ba (A) and C4BP-sup (B) 
from fig.1 and the proposed subunit composition of each form are 
shown. 
chain [23]. In the chymotrypsin digestion study [ 181, 7 
a-chain fragments were estimated to be released during 
digestion when the upper band in the C4BP doublet 
was used as starting point; starting from the lower 
band, the number of a-chains was estimated to be 6. 
These data, taken together with those of the present 
study, suggest the following conclusions regarding 
subunit composition: The ‘high’ forms of C4BP, which 
are identical in the two preparations used here, contain 
7 a-chains and one P-chain; the C4BP-low form that is 
obtained from the barium citrate supernatant and 
which lacks the protein S binding site, contains 7 (Y- 
chains but no P-chain; finally, the protein S binding 
C4BP-low that is obtained from the barium precipitate, 
contains 6 o-chains and one P-chain. This interpreta- 
tion is schematically illustrated in fig.3. It is probable 
that additional species of C4BP exist in plasma, which 
differs in subunit composition (e.g. 8 a-chains with or 
without one P-chain). 
The P-chain and the protein S binding site share 
many characteristics [23,31]. Both are located close to 
the central core of C4BP, both are susceptible to 
chymotryptic digestion but can be protected by bound 
protein S, and both are present in one copy per C4BP 
molecule. The present findings provide further support 
for the conclusion that the single protein S binding site 
of C4BP is located on the B-chain. 
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